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Normal Blood Pressure With Elevated Angiotensin II
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Abstract—Recently, the concept of local renin-angiotensin systems (RAS) capable of generating angiotensin II apart from 
the circulation has received considerable attention. To investigate this, we generated ACE 1/3 mice in which one allele 
of ACE is null and the second allele was engineered to express ACE on the surface of hepatocytes. ACE 1/3 mice 
express no endothelial ACE and lack ACE within the lungs. Their kidneys contain <7.8% the enzyme levels present 
in control mice. Plasma conversion of angiotensin I to angiotensin II was 43.3% normal. The baseline blood pressure 
and renal function of the ACE 1/3 mice were normal, probably as a function of a marked increase of both plasma 
angiotensin I and angiotensin II. When exposed to 2 weeks of a salt-free diet (a stress diet stimulating the RAS), blood 
pressure in ACE 1/3 mice decreased to 92.3±2.0 mm Hg, a level significantly lower than that of wild-type control mice. 
The ACE 1/3 mice demonstrate the plasticity of the RAS and show that significant compensation is required to maintain 
normal, basal blood pressure in a mouse with an impaired local vascular and renal RAS. (Hypertension. 2003;41:313- 
321.)
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T he renin-angiotensin system (RAS) is a principle regu­
lator of blood pressure and electrolyte homeostasis 
within the body. Inhibitors of this system have found broad 
use in the modern treatment of hypertension, congestive heart 
failure, and diabetic nephropathy. The RAS was originally 
characterized as a circulating, endocrine network, but in 
recent years the concept of a local RAS has gained consid­
erable attention. In part, this is due to the finding that multiple 
organs express all of the components necessary to recapitu­
late a functional, local RAS in situ.1-5 Although in theory, 
multiple tissues may regulate the production of angiotensin II 
independent from the circulation, the physiological and 
pathophysiological role of tissue RAS in organs such as the 
kidney and the vasculature is not known.
Recently, we engineered a mouse with an altered profile in 
its expression of ACE.6 This animal, termed ACE.3, does not 
produce vascular ACE but instead expresses the enzyme on 
the cell membrane of hepatocytes. This was accomplished by 
using targeted homologous recombination to substitute the 
control of ACE expression from its endogenous promoter to 
an albumin promoter.7 As such, the liver of the homologous 
recombinant mouse (termed ACE 3/3 to indicate two targeted 
alleles) produces 87-fold more ACE than that of a wild-type 
animal. The only extrahepatic source of tissue ACE in the
ACE 3/3 mouse is in the kidney, which has roughly 14% of 
wild-type levels. This expression is limited to the proximal 
tubule and is not observed within renal vascular endothelium 
or adventitia. This residual ACE expression is probably due 
to the specificity of the albumin promoter, since the original 
characterization of albumin promoter cassettes similar to that 
used in the ACE 3/3 mice showed low levels of reporter gene 
expression within the kidney. The systolic blood pressure of 
the ACE 3/3 is equivalent to wild-type at both baseline and 
after water deprivation, implying that endothelial ACE is not 
mandatory for the regulation of blood pressure, at least under 
these conditions.
The ACE.3 animal was created in a deliberate attempt to 
gain insight into the relative roles of the local versus 
endocrine RAS in mammalian physiology. We reasoned that 
an animal lacking vascular ACE but still capable of produc­
ing circulating angiotensin II would be a useful tool to 
address this issue. However, a limitation of the ACE.3 model 
is that it has plasma ACE activity that is 79% of wild-type, 
probably as a result of the release of hepatic ACE into the 
circulation. This level of plasma ACE in ACE 3/3 mice may 
provide substantial compensation for its lack of vascular 
ACE. To minimize this confounding variable and to minimize 
the renal tubular ACE found in the ACE.3 model, we have
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engineered a mouse that is a compound heterozygote at the 
ACE locus. This animal, termed ACE 1/3, contains one null 
allele for ACE (the ACE.1 allele) and one copy of the ACE.3 
allele. Our analysis of this animal demonstrates that it has a 
systolic blood pressure equivalent to wild-type but that it has 
a substantial elevation in its circulating levels of both angio­
tensin I and angiotensin II. In this model, we believe the 
elevated plasma levels of angiotensin II compensate for the 
lack of local ACE production. The ACE 1/3 mice not only 
demonstrate the plasticity of the RAS but also show that a 
normal blood pressure can be associated with a marked 
elevation of plasma angiotensin II levels.
Methods
Creation and Genotyping of Compound 
Heterozygous Mice
To produce ACE 1/3 compound heterozygote animals, ACE.1 
heterozygote mice (1 /+ ) were mated with ACE.3 homozygous 
mutant mice (3/3). Both the ACE.1 and the ACE.3 line were created 
by using targeted homologous recombination in R1 embryonic stem 
cells (derived from a 129/SVX129/SvJ F1 embryo) that were 
implanted in blastocysts from C57Bl/6 mice.8 The 1/+  animals used 
in matings were in the 7th generation o f back-cross to C57Bl/6 and 
the 3/3 mice were o f the F3 and F4 generation. Thus, the generated 
litters of ACE 1/3 and 3 /+  mice were neither pure C57Bl/6 strain nor 
pure 129 strain.
Mice were genotyped through the use of two independent poly­
merase chain reactions (PCR). The first amplified a fragment of 
^ 5 0 0  bp from the ACE.3 allele.6 As predicted, this reaction was 
positive for every animal examined. The second PCR reaction was 
designed to discriminate between the wild-type allele and the ACE.1 
allele. Through the use of a 3-primer system, wild-type genomic 
DNA yielded a band of 215 bp and the ACE.1 mutant allele yielded 
a band of 287 bp.9
Western Blot and ACE Activity Assays
Samples for W estern blot and tissue ACE activity were prepared in 
a manner designed to minimize plasma ACE contamination.6 ACE 
activity was measured in tissue homogenates and plasma with the 
ACE-REA kit from American Laboratory Products Company, Ltd. 
The measurement of plasma ACE conversion of angiotensin I to 
angiotensin II was performed as previously described.10
Blood Pressure Determination
Systolic blood pressure was determined with a Visitech automated 
tail-cuff system.11 To measure the blood pressure response to a 
sodium-deficient diet, a baseline blood pressure was determined for 
each mouse. The mice were then placed on a zero-sodium rodent diet 
purchased from Dyets, Inc. Highly deionized water in clean plastic 
containers was available ad libitum. During the control period, the 
mice were fed an identical diet from Dyets, Inc that was supple­
mented with 0.4% NaCl. At the end of 2 weeks, the mice were 
reacclimatized to the blood pressure machine and their systolic blood 
pressure was evaluated.
Plasma Angiotensin I and II
Angiotensin I and II levels were measured by radioimmunoassay, as 
previously described.12 The assay background was determined by 
measuring peptide levels in angiotensinogen knockout mice, animals 
genetically modified to lack angiotensin I and angiotensin II. 
Background values were subtracted from the measurements to obtain 
the final data.
Both plasma and urinary aldosterone were measured by using the 
Coat-a-Count radioimmunoassay from Diagnostic Products Corpo­
ration. Plasma renin concentration was determined as previously 
described.13 This assay measures renin concentration in the presence 
of an excess of angiotensinogen.
Plasma Volume
Plasma volume was measured as previously described, with minor 
changes.14 Mice were restrained and 0.1 mL of 1% Evans blue dye 
solution was infused into the tail vein. Blood samples were drawn 
retroorbitally 5 and 15 minutes after the dye was injected, and the 
OD620 of a 1:100 dilution of plasma was measured. An initial OD 
value at the time of dye administration (time 0) was then extrapolated 
from the two time points. This value was compared with that of 
standard dye dilutions to determine the plasma volume. Plasma 
volume was not assessed on the same group o f animals on the normal 
and zero-salt diets to eliminate error caused by residual dye in the 
circulation. Instead, a different cohort o f mice was used for each diet.
Angiotensin Peptide Infusions
Angiotensin I and II infusions were performed as previously de­
scribed, with slight modification.15 Mice were anesthetized with 125 
mg/kg ketamine and 12.5 mg/kg xylazine, and the carotid artery and 
jugular vein were cannulated. Angiotensin I and II were infused 
separately, each at two concentrations (0.1 and 1.0 ju,g/kg) in a 
volume equal to 0.1% of body weight and flushed in 50 ju,L 0.9% 
saline/50 U/mL heparin. A saline control was also infused in an 
equivalent fashion. The mice were anesthetized during the course of 
the experiment. Arterial blood pressure was monitored with the 
Digi-Med BPA-400 (Micro-Med).
Hematocrit and Urine Collection
Hematocrit was measured manually in a microcapillary reader. Urine 
osmolality was determined with a W escor 5500 Vapor Pressure 
Osmometer. For the measurement o f urinary sodium, mice were 
housed without food and water in individual metabolic cages, and 
urine was collected for 24 hours. Urinary sodium concentration was 
determ ined  w ith a Perk in  E lm er 3110 atom ic absorption  
spectrometer.
Statistical Analysis
ANOVA followed by the Tukey honest significant difference test 
and the Bonferroni t test were used for statistical comparisons 
between groups. A paired t test was used to analyze the changes in 
blood pressure within the same group. The probability value for 
significance was defined as P < 0.05.
Results
Creation of Compound Heterozygote Mice
We have previously described three strains of mice contain­
ing mutations of the ACE locus produced by using targeted 
homologous recombination in embryonic stem cells. The first 
strain (ACE.1) is a null in that homozygous animals (ACE 
1/1) produce no ACE.9 The second strain (ACE.2) is a tissue 
ACE knockout; homozygous mice (ACE 2/2) have ^40%  of 
normal plasma ACE, but tissues demonstrate no ACE protein 
or ACE activity.10 Both ACE.1 and ACE.2 homozygous 
mutant mice have a reduction in systolic blood pressure of
35 mm Hg, are anemic, and cannot produce concentrated 
urine. In contrast, ACE.3 homozygous mice (ACE 3/3) have 
normal blood pressure and a phenotype apparently identical 
to wild-type mice.
To produce litters containing compound heterozygous 
animals, ACE.1 heterozygote mice (ACE 1/+) were mated 
with ACE.3 homozygous mutant mice. The resulting off­
spring were genotyped by using PCR reactions designed to 
detect the wild-type (+), ACE 1, and ACE 3 alleles. Of 110 
pups born from these matings, 53 were ACE 3/ in genotype 
and 57 were ACE 1/3, which did not differ from the expected 
mendelian ratio of 1:1. The physiological analyses described 
in this report were performed on the offspring from these
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Figure 1. Tissue ACE. A, ACE.3 wild-type {+/+), heterozygote 
(3/+), knockout (3/3), and compound heterozygote (1/3) mice 
were killed and their lungs, liver, and kidneys homogenized. Ten 
micrograms of total protein homogenate was separated by 
SDS-PAGE and analyzed by Western blot, using a rabbit anti­
mouse ACE antibody. Somatic ACE was detected at =170 kDa, 
as indicated by arrow. Wild-type mice have little ACE in the liver 
but abundant ACE in the lung and kidney. In contrast, ACE 3/3 
and 1/3 mice express ACE in the liver but have no pulmonary 
ACE and a reduction in renal ACE. In particular, the 1/3 mouse 
expresses only a fraction of the renal ACE of the + /+  mouse.
B, ACE.3 wild-type {+ /+ , black), heterozygote (3/+, striped), 
knockout (3/3, gray), and compound heterozygote (1/3, stippled) 
mice were killed and ACE activity measured in organ homoge- 
nates. Total organ ACE activity was then calculated for the liver, 
kidneys, and lungs of each mouse and normalized for the mass 
of the mouse. The livers of 3/+, 3/3, and 1/3 mice have abun­
dant total ACE activity, partly as a result of the large size of this 
organ. ACE activity is not detected in the lung of the 3/3 and 
1/3 mice and is significantly reduced in the kidney. Whereas 
ACE 3/3 mice have =14% of the total renal ACE found in + /+  
mice, ACE 1/3 mice average 7.8% of wild-type. The number of 
mice in each group was as follows: + /+  liver, 5; 3/+ liver, 14; 
3/3 liver, 5; 1/3 liver, 9; + /+  kidney, 11; 3/+ kidney, 15; 3/3 kid­
ney, 11; 1/3 kidney, 14; + /+  lung, 5; 3/+ lung, 14; 3/3 lung, 5; 
1/3 lung, 9. All data presented are group mean±SEM.
litters (3/ and 1/3) in conjunction with F2-F4 generation 
ACE.3 mice ( +/ + ,  3/+ , and 3/3) derived from matings of 
ACE.3 heterozygotes. Except as where specifically noted in 
the text, the two groups of ACE 3/ mice were phenotypi­
cally equivalent.
ACE Expression
To verify the pattern of ACE expression in ACE 1/3 animals, 
organ homogenates were separated by SDS-PAGE and ana­
lyzed by Western blot, with a rabbit polyclonal antibody 
specific for murine ACE (Figure 1A). As expected, the lung 
of wild-type ( / ) animals contained a very large amount of 
ACE. The lung of ACE 3/ animals was also rich in ACE 
expression because of the presence of a single wild-type 
allele in these mice. In contrast, ACE 3/3 and 1/3 animals did 
not express any pulmonary ACE. Likewise, the liver of 
wild-type animals did not express any ACE. However, ACE 
3/ , 3/3, and 1/3 mice all contained hepatic ACE as the result
of the presence of the ACE.3 allele. In the kidney, wild-type 
and ACE 3/+ mice expressed abundant ACE protein, 
whereas 3/3 mice expressed substantially less. Kidney ho- 
mogenates from ACE 1/3 animals had only a very faint band 
for ACE on Western analysis. Similar to what we have 
reported in the ACE 3/3 mouse, other tissues examined in the 
ACE 1/3 animal, including the aorta, intestine, heart, and 
testis, did not express any somatic ACE (data not shown).
Another method to examine the tissue distribution of ACE 
is to measure its enzymatic activity in various organs. A 
cohort of animals was killed and their organs were individ­
ually homogenized. The ACE activity was then determined in 
a known quantity of homogenized tissue. With the use of the 
weight of each organ, the total ACE activity in the entire 
organ was estimated for each animal. The average total organ 
ACE activity for each genotype, normalized for the weight of 
individual mice, is presented in Figure 1B. The level of ACE 
activity in the liver of wild-type ( / ) mice is essentially 
zero. The ACE 1/3 and 3/+ livers each contain an interme­
diate amount of ACE activity. There was a mild but statisti­
cally significant difference in hepatic ACE activity between 
the F2 generation ACE 3/+ mice produced from F1 
3 /+X 3/+  matings (5438±613 U/g, n=6) and those produced 
from ACE 3/3XACE 1/+ matings (7624±389 U/g, n=8) 
(P < 0.05). However, neither group individually (nor when 
combined) had hepatic ACE activity statistically different 
from that observed in ACE 1/3 mice. The highest level of 
hepatic ACE activity was found in 3/3 animals. In the kidney, 
both wild-type and ACE 3/ mice had substantial ACE 
activity. As we have previously reported, the total renal ACE 
activity in 3/3 mice averaged 14% of wild-type. In ACE 1/3 
mice, the renal ACE activity decreased to 7.8% of wild-type. 
When evaluated as ACE activity per microgram of solubi­
lized protein, the ACE 1/3 mice averaged 5.3% of wild-type 
mice as opposed to 12.5% for ACE 3/3 mice.
In agreement with the data obtained from Western blots, 
the lungs of ACE 1/3 and 3/3 mice do not contain measurable 
levels of ACE activity, whereas the levels in ACE 3/ and 
wild-type ( / ) mice are quite high. Therefore, the tissue 
distribution of ACE in the 1/3 animal closely matched our 
expectations, based on its genetic makeup.
An important factor in our decision to examine the ACE 
1/3 model was the substantial level of plasma ACE in the 3/3 
mouse. To measure circulating ACE levels, mice were bled 
from the tail vein and plasma was collected by centrifuging. 
ACE activity was then assayed by using the artificial sub­
strate 3H-hippuryl-glycyl-glycine (HGG) (Figure 2A). Under 
these conditions, ACE 1/3 mice had 47.3% the plasma ACE 
activity of wild-type mice.
The molecular structure of ACE is such that it consists of 
two highly homologous catalytic domains, each of which 
participates in the physiological conversion of angiotensin I 
to angiotensin II.16 The use of artificial substrates for ACE 
comes with caveats, one being that they are selectively 
cleaved by the carboxyl-terminal catalytic domain of ACE.10 
The most physiologically appropriate method to measure 
ACE activity in the plasma of ACE 1/3 mice is to assess the 
rate of conversion of angiotensin I to angiotensin II (Figure 
2B). In particular, this assay permits a comparison to be made
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Figure 2. Plasma ACE. A, ACE.3 wild-type (+/+), heterozygote 
(3/+), knockout (3/3), and compound heterozygote (1/3) mice 
were bled from the tail vein, and plasma was isolated. Plasma 
ACE activity was assayed with the artificial substrate 3HGG. 
Plasma ACE activity in 1/3 mice is =47% of wild-type. Number 
of mice in each group was as follows: (+/+), 16; (3/+), 26; (3/3), 
24; (1/3), 17. All data presented are the group mean±SEM. B, 
Plasma was collected from the groups shown in A along with 
ACE.2 knockout mice (2/2) and plasma ACE activity was deter­
mined by using the physiological substrate angiotensin I.
Plasma of ACE 1/3 and 2/2 mice converts angiotensin I to an­
giotensin II at an approximately equal rate. Both groups have 
significantly less plasma ACE activity than + /+ , 3/+, or 3/3 
mice (P<0.01 for all comparisons). The number of mice in each 
group was as follows: (+/+), 12; (3/+), 4; (3/3), 6; (1/3), 12;
(2/2), 4. All data presented are group mean±SEM.
between the plasma ACE activity in the ACE 1/3 mouse and 
the ACE.2 knockout (2/2), an animal that secretes a truncated 
form of ACE containing only the amino-terminal domain. In 
the conversion of angiotensin I to angiotensin II, ACE 1/3 and 
2/2 mice have 43.3% and 37.0% of wild-type plasma ACE 
activity, respectively. These values, although not statistically 
different from one another, are significantly decreased from 
the levels observed in ACE 3/3, 3/+, or + /+  mice (P < 0.01). 
This finding is relevant because the blood pressure and 
plasma angiotensin II levels of ACE 2/2 animals are quite 
low. Specifically, the blood pressure of ACE 2/2 mice 
averaged 75 mm Hg versus 110 mm Hg for wild-type control 
mice, and plasma angiotensin II levels averaged 21.8% of 
wild-type.1017 Thus, the level of plasma ACE present in the 
ACE 2/2 animal is not sufficient for the normal regulation of 
blood pressure. This suggests that the residual plasma ACE 
activity in the ACE 1/3 mouse is also not sufficient to
Figure 3. Response to angiotensin peptide infusion. The jugular 
vein of ACE + /+ , ACE 1/3, and ACE 2/2 mice was cannulated 
(n=4 for each group) and angiotensin I and angiotensin II were 
infused separately, each at two concentrations (0.1 and 1.0 
/j.g/kg). The peak increase in mean arterial pressure after drug 
infusion was monitored with an arterial catheter. There was no 
difference in response among the three genotypes to either 
dose of angiotensin II. When angiotensin I was infused, the 
blood pressure increase in ACE 2/2 mice was significantly atten­
uated as compared with wild-type at both 0.1 /xg/kg (*P<0.05) 
and 1.0 /xg/kg (**P<0.01). Response of ACE 1/3 was also 
reduced compared with wild-type at 1.0 /xg/kg (*P<0.05). Infu­
sion of saline alone (vehicle control) led to an average pressure 
increase of 2.9±0.7 mm Hg in the 12 mice studied. All data are 
presented as group mean±SEM.
generate angiotensin II in ample quantity for normal blood 
pressure homeostasis.
Physiological Analysis
As indicated, ACE 1/3 and ACE 2/2 mice have roughly 
equivalent plasma ACE activity. However, because of liver 
expression of ACE, the total enzyme available in an ACE 1/3 
animal is greater than that found in the ACE 2/2 model. To 
quantify this, we measured the peak change in mean arterial 
pressure in wild-type, ACE 1/3, and ACE 2/2 mice after 
intravenous infusion of either angiotensin I or II (Figure 3). 
The effect of each peptide was assessed at two separate 
infusion dosages (0.1 and 1.0 /xg/kg). Although all three 
groups had a similar increase in blood pressure in response to 
angiotensin II, there was a large discrepancy in the response 
to angiotensin I. Wild-type mice showed a rise of blood 
pressure averaging 52.1 ±5.2 mmHg in response to 1.0 
g/kg angiotensin I. In contrast, the ACE 2/2 animals showed 
a markedly reduced response, averaging just 5.2± 1.3 mm Hg 
in response to the same dosage. The response of the ACE 1/3 
animal to infused angiotensin I was present but was more 
complicated. At the low dose of angiotensin I, the rise of 
blood pressure was similar to that of wild-type mice. How­
ever, at an infusion of 1.0 /xg/kg angiotensin I, the ACE 1/3 
mice had an attenuated response compared with wild-type 
(31.5±6.4 mmHg, P < 0.05). Such a result suggests that the 
total body load of ACE present in the ACE 1/3 model is 
significantly more than in the ACE 2/2 animals but less than 
that present in a wild-type mouse.
In a wild-type animal, the vast majority of ACE activity is 
closely associated with the endothelium, permitting the pro­
duction of angiotensin II in close proximity to underlying 
vascular smooth muscle. The ACE 1/3 animal completely 
lacks endothelial ACE and has a 50% reduction in circu-
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Figure 4. Systolic blood pressure. Baseline systolic blood pres­
sure was determined for a cohort of ACE.3 wild-type {+/+), het­
erozygote (3/+), knockout (3/3), and compound heterozygote 
(1/3) mice over 4 consecutive days by using an automated tail- 
cuff manometer. Systolic blood pressure for each mouse (M) is 
the average of 80 individual measurements. Solid bar represents 
average for each group of mice. There is no significant differ­
ence in systolic blood pressure between the groups. The num­
ber of mice was as follows: {+/+), 16; (3/+), 25; (3/3), 16; (1/3), 
17.
lating ACE. To assess the effect this has on blood pressure, 
the systolic blood pressure of a large group of mice was 
determined with an automated tail-cuff manometer (Figure
4). The blood pressure of each animal was recorded as the 
average of 80 individual data points taken over a 4-day 
period. The average blood pressure of 17 ACE 1/3 mice was 
104.7± 1.4 mm Hg, as compared with 105.^± 1.7 mm Hg for
25 ACE 3/+ mice and 105.2±2.6 mmHg for 16 wild-type 
( / ) mice. The blood pressure of individual / mice 
ranged from 83.6 to 125.0 mm Hg and for ACE 1/3 mice the 
blood pressure ranged from 90.4 to 116.0 mmHg. Thus, the 
blood pressure of 1/3 mice was not different from wild-type 
values either in average or in spread. These data indicate that 
the RAS is capable of compensating for the lack of local 
vascular production of angiotensin II in the control of blood 
pressure.
To gain further insight into the mechanism of blood 
pressure regulation in ACE 1/3 mice, we measured basal 
plasma angiotensin I and II levels (Figures 5A and 5B). The 
ACE 1/3 has significantly higher circulating angiotensin II 
peptide than wild-type ( / ), 3/ , or 3/3 mice (404 82 
pg/mL for 1/3 mice versus 137±20 pg/mL for + / + ,  184±  19 
for 3/+ , and 172±18 for 3/3; P < 0.01 for all comparisons). 
Although the level of angiotensin II was the lowest in / 
mice, this value did not significantly differ from ACE 3/ or 
3/3 mice. The ACE 1/3 animal also demonstrates a significant 
increase in plasma angiotensin I concentration as compared 
with the other genotypes (9046±1202 pg/mL for ACE 1/3 
mice versus 2911±658 pg/mL for wild-type, 3004±551 for 
ACE 3/+ , and 4474±986 for ACE 3/3; P < 0.01 for all 
comparisons). The trend toward an increase of angiotensin I 
in ACE 3/3 animals did not reach statistical significance.
Plasma renin concentration (PRC) was also measured in 
ACE + / + ,  3/+ , 3/3, and 1/3 mice while on a normal salt diet
(solid bars, Figure 5C). In agreement with the angiotensin 
peptide data, PRC was significantly elevated in the ACE 1/3 
animal as compared with ACE / , ACE 3/ , and ACE 3/3 
control mice (P < 0.01). The PRC was also increased in ACE 
3/3 animals as compared with / wild-type control mice 
(P < 0.05). These data provide evidence for the substantial 
plasticity of the RAS in the physiological regulation of blood 
pressure. The ACE 1/3 mouse not only has a shift in its 
distribution of ACE, but it also has a reduction in total body 
ACE activity. The combination of these stressors causes the 
RAS to greatly increase plasma renin and angiotensin I in 
order to generate sufficient angiotensin II for the maintenance 
of normal resting blood pressure.
As indicated above, we hypothesize that the increase of 
plasma angiotensin II present in the ACE 1/3 mice is a 
mechanism to maintain blood pressure in the face of an 
impaired local RAS. Alternatively, the elevation of angioten­
sin II could be in response to a reduction of plasma volume. 
To investigate this, we measured the plasma volume of ACE 
+/ + ,  3/+, 3/3, and 1/3 mice by the method of dye dilution 
(Figure 6). There was no difference in plasma volume 
between the four genotypes, leading to the conclusion that the 
elevation in circulating angiotensin II in the ACE 1/3 is not 
associated with volume-depletion.
ACE 1/3 mice have normal serum electrolytes including 
serum sodium, potassium, chloride, blood urea nitrogen, and 
creatinine (Table). The plasma aldosterone concentration and 
urinary aldosterone excretion of ACE 1/3 mice were also not 
significantly different from wild-type, ACE 3/ , or ACE 3/3 
animals. Light microscopic examination of the kidneys of the 
ACE 1/3 mice showed a normal renal architecture, including 
a normal renal medulla and papilla. Normal rodents are able 
to produce urine that is concentrated in excess of 3000 
mOsm/kg H2O. In contrast, mice lacking all ACE (ACE 1/1) 
or all tissue ACE (ACE 2/2) cannot concentrate urine beyond 
^1000 mOsm/kg H2O. Because ACE 1/3 compound het­
erozygotes are 90% deficient in renal ACE, we investigated 
whether they could generate a maximally concentrated urine. 
A spot of urine was collected from 17 ACE 1/3 and 6 3/ 
mice both at baseline and after 24 hours of water deprivation. 
Under each condition, the osmolality of the ACE 1/3 urine 
was equivalent to that observed in ACE 3/+ mice (2036± 185 
mOsm/kg H2O at baseline and 3455 ±27 mOsm/kg H2O after 
water deprivation for 1/3 mice versus 2286 143 mOsm/kg 
H2O at baseline and 3481±52 mOsm/kg H2O for 3/+ mice). 
Thus, it is clear that despite a tremendous reduction in renal 
ACE ( 90%), the ACE 1/3 mice maintain a normal renal 
concentrating ability.
Another phenotype observed in ACE.1 and ACE.2 knock­
out mice was a normocytic, normochromic anemia.17 Al­
though the cause underlying the anemia is not fully under­
stood, it is a true anemia characterized by an 25% reduction 
in circulating red cell mass. When we examined the hemat­
ocrit of the ACE 1/3 mouse, it averaged 0.548±0.005 
(54.8±0.5%) (n= 17) versus 0.552±0.005 (55.2±0.5%e) 
(n=9) in littermate 3/+ mice (P=NS). Thus, the ACE 1/3 
animal has sufficient residual ACE activity to prevent the 
development of anemia.
Downloaded from hyper.ahajournals.org at UNIV OF UTAH on November 2, 2009
318 Hypertension February 2003
Figure 5. Plasma angiotensin peptide levels. Anesthetized mice 
were bled by cardiac puncture, and plasma was immediately 
frozen. Plasma angiotensin I and angiotensin II peptide levels 
were determined by radioimmunoassay. The number of mice in 
each group was as follows: (4 /4 ), 14; (3/4 ), 27; (3/3), 13; (1/3), 
13. A, ACE 1/3 mice have marked elevation of plasma angioten­
sin II as compared with 4 /4 , 3/4 , or 3/3 mice (P<0.01). B, 
Plasma angiotensin I levels are also significantly increased in 
ACE 1/3 mice as compared with the other groups (P<0.01). The 
data also show a trend toward higher plasma angiotensin I lev­
els in ACE 3/3 mice as compared with 4 /4 and 3/4 mice, 
although this did not reach statistical significance. C, Mice on a 
standard (0.4% NaCl) diet were exsanguinated and plasma renin 
concentration (PRC) was measured (black bars). ACE 3/4 and 
1/3 mice were also studied after >3 weeks on a zero sodium 
diet (striped bars). On the normal diet, the PRC of ACE 1/3 mice 
averaged 681 ±83%, 323±39%, and 204±25% that found in 
wild-type (4 /4 ), ACE 3/4 , or ACE 3/3 mice, respectively
Figure 6. Plasma volume. The plasma volume of ACE 4 /4 ,
3/4 , 3/3, and 1/3 mice was measured by the intravascular infu­
sion of Evans blue dye. There is no difference in average plasma 
volume between the groups. The presence of a normal plasma 
volume and a normal hematocrit in the ACE 1/3 mouse indi­
cates that the animal is not volume-depleted. All data are pre­
sented as group mean±SEM. The number of mice in each 
group was as follows: (4 /4 ), 8; (3/4 ), 9; (3/3), 8; (1/3), 9.
Sodium Depletion
The ability of ACE 1/3 animals to maintain a wild-type 
phenotype indicates the tremendous flexibility of the RAS. 
However, to preserve this normal phenotype, the ACE 1/3 
mouse must increase substantially both angiotensin I and 
angiotensin II. This suggests that the RAS may be approach­
ing its maximum ability to compensate in this model and 
raises the question of how the ACE 1/3 animal would respond 
to physiological stress. To investigate this, we placed ACE 
+/ + ,  3/+, 3/3, and 1/3 animals on a diet lacking NaCl for 2 
weeks, a condition that should maximally activate the RAS. 
The food intake and body weight were monitored for a subset 
of 1/3 and 3/+ mice (n=6 to 10 in each group). On both diets, 
the ACE 1/3 mice consumed a slightly larger percentage of 
their body weight daily than littermate 3/ animals 
(10.6±2.0% and 8.8±1.7% for ACE 1/3 mice on the normal- 
sodium and zero-sodium diets, respectively, versus 
8.9±1.2% and 7.3±2.3% for 3/+ mice, P < 0.05 for all 
comparisons). Neither group had a significant change in body 
weight during 2 weeks of sodium deprivation. The plasma 
volume was also assessed for a group of 7 3/ and six 1/3 
mice after 2 weeks of sodium restriction. The average 
plasma volume of 3/+ and 1/3 mice decreased by 12.5% and 
9.1%, respectively, as compared with similar mice on the
(**P<0.01). Under these conditions, the PRC of ACE 3/3 mice 
was also significantly increased as compared with wild-type 
control mice (P<0.05). On the zero sodium diet, the PRC of 
ACE 1/3 mice was elevated >15-fold as compared with wild- 
type mice on a normal diet. This measurement was highly signif­
icant as compared with littermate ACE 3/4 mice on the zero 
sodium diet or ACE 1/3 mice at baseline (***P<0.001). The num­
ber of mice in each group was as follows: 4 /4 normal salt, 7; 
3/4 normal salt, 8; 3/3 normal salt, 8; 1/3 normal salt, 8; 3/4 
zero salt, 9; 1/3 zero salt, 6. The elevation of renin, angiotensin
I, and angiotensin II indicates a physiological compensation by 
the RAS to sustain systolic blood pressure. All data presented 
are group mean±SEM.
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C haracteristics of ACE Mice
Parameter +/+ 3/+ 3/3 1/3
Serum sodium, mEq/L 147,8±0.4 (8) 147,8±0.8 (8) 148.5±0.4 (6) 148.4± 1.1 (7)
Serum potassium, mEq/L 4.41 ±0.12 (8) 4,29±0.16 (8) 4.33 ±0.23 (9) 4.20±0.21 (7)
Serum chloride, mEq/L 111,8± 1.0 (8) 113.4±0,8 (8) 113.3 ±0.8 (6) 112.1 ±1.1 (7)
Serum BUN, mg/dL 25.3± 1.3 (8) 26.9±4,9 (8) 24,0±2,6 (6) 23.1 ±1.3 (7)
Serum creatinine, mg/dL 0.24±0.02 (8) 0.24±0.02 (8) 0.24±0.02 (9) 0.27±0.02 (7)
Plasma Aldo (normal diet), pg/mL 913± 97 (7) 699±60 (8) 779 ±129 (8) 565 ±31 (8)
Plasma Aldo (zero salt diet), pg/mL ND 2041 ±520 (6) ND 2088 ±767 (6)
Urinary Aldo (normal diet), pg/mL 1475± 116 (6) 1583 ±120 (6) 1410 ±210 (6) 1715± 152 (6)
Urinary Aldo (zero salt diet), pg/mL 4321 ±1047 (6) 4930 ±665 (6) 6994 ±1937 (6) 5945 ± 2033 (6)
ACE.3 wild-type (+/+), heterozygote (3/+), knockout (3/3), and compound heterozygote (1/3) mice were studied 
for the parameters listed in the table. Number of animals in each group is given in parentheses and all data are 
presented as the mean±SEM, BUN, indicates blood urea nitrogen; Aldo, aldosterone; ND, no data.
normal sodium diet. Although this reduction in plasma 
volume was statistically significant as compared with mice on 
a normal salt diet (P < 0.01), the magnitude of decrease was 
not significantly different between the 1/3 and 3/ mice.
Twenty-four-hour urinary sodium excretion was deter­
mined for each mouse while on the normal salt diet and after 
2 weeks of salt depletion (Figure 7A). On the baseline 
(normal sodium) diet, there was no significant difference in 
sodium excretion between the genotypes. All groups showed 
a marked reduction of sodium excretion on the salt-free diet. 
Under these conditions, the 1/3 mice appear to excrete the 
most salt, though the differences between all groups are 
small. In fact, the only statistical comparison attaining sig­
nificance is between ACE 3/+ and ACE 1/3 mice (P < 0.05). 
However, these trends in salt excretion parallel the changes in 
blood pressure described below.
Systolic blood pressure was determined over a 4-day 
period at baseline and after 2 weeks on the altered diet (Figure 
7B). At baseline, there were no significant differences in 
average blood pressure between the 4 genotypes. After 2 
weeks without NaCl, the average blood pressure of both 3/ 
and 1/3 mice decreased significantly from baseline levels 
(P < 0.05 and P < 0.01 respectively). However, the drop in 
blood pressure was greater in ACE 1/3 mice than that 
observed in ACE 3/+ mice (9.7±2.3 mmHg for ACE 1/3 
mice versus 5.0 2.1 mm Hg for ACE 3/ mice). Among 
+ / + ,  3/+ , 3/3, and 1/3 animals, the ACE 1/3 mice also had 
the lowest average systolic blood pressure on the sodium- 
deficient diet, although the only comparison that attained 
statistical significance was between / and 1/3 mice 
(P < 0.05). After sodium restriction, the PRC of both ACE 1/3 
and 3/ mice was significantly elevated as compared with 
mice of the same genotype on a normal salt diet (Figure 5C, 
P < 0.001). With a sodium-free diet, the PRC of the ACE 1/3 
mice averaged 1552 161% that of wild-type mice on a 
normal salt diet and 277 29% that of littermate ACE 3/ 
mice on the zero salt diet. Urinary aldosterone excretion 
showed a marked increase in all mice on the salt-free diet 
(Table). No statistical differences were noted between differ­
ent genotypes. The salt depletion experiment demonstrated a 
subtle difference in the response of the ACE 1/3 mouse to 
physiological stress. However, it is noteworthy that even after
2 weeks of strict sodium depletion, ACE 1/3 mice sustain a 
systolic blood pressure of 90 mm Hg.
Discussion
The difference between a wild-type mouse and a knockout 
animal lacking all ACE is significant; the knockout has a 
striking reduction of blood pressure, serum electrolyte abnor­
malities, renal pathology, the inability to concentrate urine, 
anemia, and a marked reduction of male fertility.9,18 This 
complex phenotype indicates the many roles of the renin-an- 
giotensin system. It also emphasizes that the animal null for 
all ACE expression is very different from a wild-type mouse. 
To study the function of the RAS in a more selective fashion, 
we used homologous recombination to place the structural 
portions of the ACE gene under the control of the albumin 
promoter. The ACE 3/3 mouse lacks endothelial ACE but 
produces large amounts of ACE in the liver. The idea was to 
investigate if the RAS could function if reconfigured with 
abundant ACE in an aberrant location. The answer is yes in 
that this animal model has a normal physiology, including a 
normal blood pressure. In analyzing the ACE 3/3 model, we 
were faced with two problems: the role of the residual renal 
ACE and the role of circulating plasma ACE. To address 
these issues, we created the ACE 1/3 mouse.
The ACE 1/3 animal is perhaps a more useful model to 
investigate the role of vascular and renal tubular ACE in 
blood pressure homeostasis. Like the ACE 3/3 mice, ACE 1/3 
animals have no endothelial ACE but do express ACE on the 
surface of hepatocytes. Importantly, the ACE 1/3 model has 
much less circulating ACE than that present in ACE 3/3 
animals. In fact, the plasma ACE levels are nearly equivalent 
to those in ACE 2/2 mice, animals lacking all tissue ACE. In 
the ACE 2/2 model, the circulating ACE is unable to elevate 
plasma angiotensin II levels much above the levels seen in 
mice totally deficient in ACE. Because of this, ACE 2/2 mice 
have a phenotype similar to ACE null mice, including a 
profound reduction of blood pressure. Thus, it seems very 
unlikely that the plasma ACE present in ACE 1/3 mice 
contributes much to the normal blood pressure in these 
animals.
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F ig u re  7. Response to sodium-deficient diet. Urinary sodium 
excretion and systolic blood pressure of ACE H /H , 3/H , 3/3, 
and 1/3 mice were evaluated at baseline and after 2 weeks of a 
sodium-free diet. A, Urinary sodium excretion. On a normal 
sodium diet (black bars), there is no significant difference 
between the four genotypes. Daily sodium excretion is markedly 
decreased in all genotypes after 2 weeks of a salt-free diet (gray 
bars). In this condition, 1/3 mice appear to excrete slightly more 
salt than H /H , 3/H , or 3/3 animals, although only the difference 
between 1/3 and 3/H attained statistical significance (P<0.05). 
The number of mice in each group was as follows: H /H normal 
salt, 12, H /H zero salt, 6; 3/H normal salt, 12, 3/H zero salt, 13; 
3/3 normal salt, 14; 3/3 zero salt, 13; 1/3 normal salt, 13; 1/3 
zero salt, 13. B, Systolic blood pressure. At baseline (black 
bars), the average blood pressure was not different between the 
groups. After 2 weeks on the altered diet (gray bars), the blood 
pressure of both ACE 3/H and 1/3 mice significantly decreased 
from baseline levels (P<0.05 and P<0.01, respectively). In this 
state, the average blood pressure of the ACE 1/3 mice was 
lower than the other three genotypes, although only the differ­
ence between H /H and 1/3 mice was statistically significant 
(P<0.05). All data presented are the group mean±SEM. The 
number of mice in each group was as follows: (H /H ), 9; (3/H ),
14; (3/3), 11; (1/3), 8.
The kidney is another organ that expresses abundant ACE 
in endothelium, proximal tubular epithelium, and glomerular 
mesangial cells. All the components of the RAS are expressed 
in the kidney and it is logical to assume that a local, intrarenal 
RAS may participate in renal function and in the regulation of 
blood pressure. Mice that overexpress human angioten- 
sinogen selectively in the proximal tubule (and human renin
systemically) have systolic blood pressure 20 mm Hg 
higher than either nontransgenic mice or those expressing 
either transgene alone,19 providing some evidence for the 
physiological significance of the local renal RAS in vivo. 
Angiotensin II is thought to promote renal concentrating 
ability both through direct effects on the nephron and though 
indirect effects, such as stimulating aldosterone release. Mice 
lacking angiotensinogen, ACE, the AT1A receptor, or both 
AT1A and AT1B receptors cannot produce a concentrated 
urine, and in wild-type mice, the administration of the AT1 
antagonist losartan is sufficient to reduce urine osmolality 
(reviewed by Oliverio and Coffman20). We have also recently 
reported that ACE 2/2 mice have reductions in several 
medullary transporters, including UT-A1, ClC-K1, NKCC2/ 
BSC1, and AQP1.21 However, the precise role of renal ACE 
and angiotensin II in the urine concentrating mechanism is 
not well understood. In the ACE 1/3 mouse, the kidney 
contains roughly 5.3% to 7.8% the ACE level present in the 
kidney of a wild-type mouse. This level is significantly less 
than within the kidney of ACE 3/3 mice. It is impossible to 
know if these very low renal ACE levels are of physiological 
consequence. However, the presence of apparently normal 
renal function in the ACE 1/3 model suggests either no 
crucial role of a local RAS in the kidney or a system able to 
function with an extremely low threshold for renal ACE 
expression.
The most unusual feature of the ACE 1/3 model is the 
presence of a marked elevation of plasma angiotensin I and 
angiotensin II peptides in animals with a normal blood 
pressure. This occurs in conjunction with a substantial eleva­
tion of plasma renin concentration, indicating a large increase 
in the activity of the circulating RAS. Although the precise 
signal that leads to this upregulation is not clear, it is possible 
that it is a compensatory response to a decrease in extracel­
lular fluid volume. To examine this possibility, we measured 
the plasma volume of ACE 1/3 mice and did not find it to be 
different from control. It seems logical that the increase in 
angiotensin I and angiotensin II peptides represent a response 
to the altered state of the RAS and emphasize the concept of 
ACE body load. In a wild-type mouse, ACE is abundant and 
is present both systemically and locally to produce appropri­
ate levels of angiotensin II. In the ACE 3/3 mouse, there is 
still abundant ACE with sufficient quantities in the liver and 
plasma to maintain ACE body load and produce appropriate 
angiotensin II. In contrast, both the ACE.1 heterozygote 
(ACE 1/ ) and the ACE.2 heterozygote (ACE 2/ ) have a 
reduction of ACE body load to 60% normal. These mice 
respond with elevated angiotensin I, resulting in normal 
plasma angiotensin II levels and a normal blood pressure. A 
different situation is present in the ACE 1/3 mice. Total body 
ACE levels are roughly equivalent to those in the ACE.2 
heterozygotes. However, both the lack of endothelial ACE 
and the reduced ACE present in plasma preclude the local 
production of angiotensin II. The ACE 1/3 mice respond by 
elevating both plasma angiotensin I and angiotensin II to 
levels sufficient to overcome any lack of local production and 
to establish a normal physiology under basal conditions. This 
includes not only a normal resting systolic blood pressure but
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also normal basal aldosterone levels and renal concentrating 
ability.
The ACE 1/3 mice demonstrate the homeostatic capacity 
inherent in the RAS. However, any system will have a 
threshold beyond which it cannot compensate, and we pos­
tulated that ACE 1/3 mice might be vulnerable to conditions 
of stress associated with upregulation of the RAS. This was 
tested with a 2-week diet free of salt. Under these extreme 
conditions, we found a subtle difference in the phenotype of 
the ACE 1/3 mice from control mice. The ACE 1/3 mice 
appear to have a very slight reduction in the ability to 
maximally retain salt. After 2 weeks on a salt-free diet, this 
results in a slight reduction of blood pressure as compared 
with wild-type control mice.
That ACE 1/3 mice have an elevation of plasma angioten­
sin I can be predicted by the reduction in total ACE load in 
these animals. However, we did not predict that the reduction 
in ACE alone would induce elevated angiotensin II in the 
animals. As plasma angiotensin II levels may serve as a proxy 
for the activity of the endocrine RAS, it is probable that the 
increase in plasma angiotensin II in the ACE 1/3 mice is a 
compensation for the loss of local RAS. Thus, the ACE 1/3 
animal indicates that the selective expression of hepatic ACE 
permits the normal regulation of systolic blood pressure and 
renal function in the mouse, but only after significant com­
pensation by the RAS.
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